Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022
HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ — Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an overview of the key elements of the BB-301 Phase 1b/2a clinical trial design. The…
Comments Off on Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022